215878-20-9

Basic information

• Product Name: 3-(4-PIPERIDINYL)-1,3-BENZOXAZOL-2(3H)-ONE
• Synonyms: 3-(4-PIPERIDINYL)-1,3-BENZOXAZOL-2(3H)-ONE;3-(piperidin-4-yl)benzo[d]oxazol-2(3H)-one;3-(4-piperidinyl)-2(3H)-Benzoxazolone;-1,3-benzoxazol-2(3H);3-(4-Piperidinyl)
• CAS NO: 215878-20-9
• Molecular Formula: C₁₂H₁₄N₂O₂
• Molecular Weight: 218.26
• Mol File: 215878-20-9.mol

Chemical Properties

• Boiling Point: 355.8°C at 760 mmHg
• Flash Point: 169°C
• Appearance: /
• Density: 1.259g/cm³
• Vapor Pressure: 3.05E-05mmHg at 25°C
• Refractive Index: 1.596
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• CAS DataBase Reference: 3-(4-PIPERIDINYL)-1,3-BENZOXAZOL-2(3H)-ONE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(4-PIPERIDINYL)-1,3-BENZOXAZOL-2(3H)-ONE(215878-20-9)
• EPA Substance Registry System: 3-(4-PIPERIDINYL)-1,3-BENZOXAZOL-2(3H)-ONE(215878-20-9)

Safety Data

• Hazardous Substances Data: 215878-20-9(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Synthesis:
3-(4-PIPERIDINYL)-1,3-BENZOXAZOL-2(3H)-ONE is used as a chemical building block for the synthesis of various pharmaceutical compounds. Its unique structure and functional groups make it a valuable component in the development of new drugs with potential therapeutic applications.
Used in Agrochemical Synthesis:
In the agrochemical industry, 3-(4-PIPERIDINYL)-1,3-BENZOXAZOL-2(3H)-ONE is utilized as a key intermediate in the creation of agrochemicals. Its incorporation can lead to the development of novel pesticides or other agricultural chemicals that may offer enhanced efficacy or selectivity.
Used in Biological Research:
3-(4-PIPERIDINYL)-1,3-BENZOXAZOL-2(3H)-ONE is employed as a research tool in biological studies, particularly for investigating its role as a serotonin receptor antagonist. This application aids in understanding its potential impact on biological systems and may contribute to the discovery of new therapeutic agents targeting the serotonin system.

InChI:InChI=1/C12H14N2O2/c15-12-14(9-5-7-13-8-6-9)10-3-1-2-4-11(10)16-12/h1-4,9,13H,5-8H2

Upstream product

• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 162045-48-9 1-(tert-butoxycarbonyl)-4-[(2-hydroxyphenyl)amino]piperidine 
• 32315-10-9 bis(trichloromethyl) carbonate 
• 95-55-6 2-amino-phenol 
• 162045-53-6 tert-butyl-4-(2-oxobenzo[d]oxazole-3-(2H)-yl)piperidin-1-carboxylate 

Downstream Products

• 173842-04-1 5-Chloro-1,1-dioxido-2-(4-(4-(2-oxo-3-benzoxazolinyl)-piperidin-1-yl)-butyl)-1,2-benzisothiazol-3(2H)-one 
• 204696-88-8 1-[N²-[N-[[4-[2(3H)-oxobenzoxazol-3-yl]-1-piperidinyl]carbonyl]-3,5-dibromo-D-tyrosyl]-N⁶-(1,1-dimethylethoxycarbonyl)-L-lysyl]-4-(4-pyridinyl)-piperazine 
• 400797-17-3 3-(1-{3-[5-Acetyl-3-(4-bromo-phenyl)-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl]-2-hydroxy-propyl}-piperidin-4-yl)-3H-benzooxazol-2-one 

Relevant articles and documents

HETEROCYCLIC COMPOUND, APPLICATION THEREOF, AND COMPOSITION CONTAINING SAME

A heterocyclic compound represented by formula XI, a pharmaceutically acceptable salt, a solvate, or a solvate of a pharmaceutically acceptable salt thereof, use thereof, and a composition containing the same. The compound is novel in structure and has good STAT5 inhibitory activity.

DIPHENYLBUTYPIPERIDINE AUTOPHAGY INDUCERS

Autophagy inducing compounds, methods of their preparation and use, and kits containg said compounds are disclosed herein.

Piperidine amides as 11β-hydroxysteroid dehydrogenase type 1 inhibitors

A series of piperidine amide inhibitors of human 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) were identified via modifications of the HTS hit compound 1. The synthesis, in vitro biological evaluation, and structure-activity relationship of these co

Method for treating allergies using substituted pyrazoles

A method for treating an allergic condition, including an atopic allergic condition, using substituted pyrazoles.

Design and synthesis of N-alkylated saccharins as selective α-1a adrenergic receptor antagonists

Benign prostatic hyperplasia can be managed pharmacologically with α-1 adrenergic receptor antagonists. Agents that demonstrate selectivity for the α-la receptor subtype may offer advantages in clinical applications with respect to hypotensive side effect